Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulse Biosciences CS (NQ: PLSE )

10.74 -1.21 (-10.13%)
Streaming Delayed Price Updated: 2:47 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 131,910
Open 11.71
Bid (Size) 10.70 (1)
Ask (Size) 10.80 (1)
Prev. Close 11.95
Today's Range 10.74 - 12.00
52wk Range 3.780 - 13.62
Shares Outstanding 54,902,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire

Performance

YTD
-2.54%
-2.54%
1 Month
+56.56%
+56.56%
3 Month
+13.65%
+13.65%
6 Month
+47.73%
+47.73%
1 Year
+64.98%
+64.98%

More News

Read More
Pulse Biosciences Enhances Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024
Via InvestorPlace
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023
Via InvestorPlace
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Oxford Industries, PVH And 3 Stocks To Watch Heading Into Monday
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Plans to Initiate a Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Earnings Scheduled For March 28, 2024
Via Benzinga
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Exposures Product Safety
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
From Pulse Biosciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.